"L'Institut du Cancer Courlancy Reims (ICC Reims) vous souhaite la bienvenue. Tout au long de vos soins, nos équipes médicales sont à votre disposition. L'Institut vous propose une expertise complète, de l'attention et de l'écoute pour vous assurer un confort et des soins de qualité optimale dans le seul souci de rendre ces moments difficiles plus agréables. Nous lions avec vous une relation de confiance, sincère et respectueuse."

During the past decade, Institut du Cancer COURLANCY conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 4 clinical trials were completed, i.e. on average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 1 clinical trials started and 3 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Institut du Cancer COURLANCY" #1 sponsor was "Hoffmann-La Roche" with 7 trials, followed by "ARCAGY/ GINECO GROUP" with 4 trials sponsored, "Central Hospital, Nancy, France" with 1 trials sponsored, "Centre Jean Perrin" with 1 trials sponsored and "UNICANCER" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Institut du Cancer COURLANCY" #1 collaborator was "Breast International Group" with 2 trials as a collaborator, "Alliance Foundation Trials (AFT)" with 1 trials as a collaborator, "AstraZeneca" with 1 trials as a collaborator, "CHU de Reims" with 1 trials as a collaborator and "CRLCC Val d'Aurelle, Montpellier" with 1 trials as a collaborator. Other collaborators include 18 different institutions and companies that were collaborators in the rest 28 trials.

According to Clinical.Site data, the most researched conditions in "Institut du Cancer COURLANCY" are "Breast Cancer" (8 trials), "Ovarian Cancer" (2 trials), "Breast Neoplasms" (1 trials), "Medulloblastoma" (1 trials) and "Relapsed Ovarian Cancers Patients" (1 trials). Many other conditions were trialed in "Institut du Cancer COURLANCY" in a lesser frequency.

Most popular intervention types in "Institut du Cancer COURLANCY" are "Drug" (13 trials), "Device" (1 trials), "Diagnostic Test" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (5 trials), "Trastuzumab" (4 trials), "Cyclophosphamide" (3 trials), "Docetaxel" (3 trials) and "Pertuzumab" (3 trials). Other intervention names were less common.

The vast majority of trials in "Institut du Cancer COURLANCY" are 7 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Institut du Cancer COURLANCY". undefined are not yet recruiting, undefined are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 8 completed trials in Institut du Cancer COURLANCY, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Institut du Cancer COURLANCY, 0 "Phase 1" clinical trials were conducted, 4 "Phase 2" clinical trials and 7 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 1 trials that are defined as “Not Applicable".